Latest Articles
CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells - themarijuanaherald.com
CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells themarijuanaherald.com
Published: Sept. 23, 2026, 5:01 p.m.
CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells - The Marijuana Herald
CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells The Marijuana Herald
Published: Sept. 23, 2026, 5:01 p.m.
Endometriosis as a Silent Emerging Malignant Threat in Young Women: A Case Report of Rare Rapid Transformation of Abdominal Wall Endometriosis Into Mixed High-Grade Serous and Clear Cell Carcinoma One Year Following Cesarean Section.
Abdominal wall endometriosis most commonly occurs in cesarean section (CS) scars. Although malignant transformation is rare, clear cell carcinoma (CCC) is the most commonly reported histological subtype. We present an …
Published: Aug. 6, 2026, midnight
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - Clinical Oncology News
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer Clinical Oncology News
Published: Aug. 3, 2026, 3:32 p.m.
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer - clinicaloncology.com
Pembrolizumab Monotherapy Beats Chemotherapy in Front-Line dMMR Endometrial Cancer clinicaloncology.com
Published: Aug. 3, 2026, 3:31 p.m.
Impact of the Etiology of Diminished Ovarian Reserve on Assisted Reproductive Technology Outcomes: A Multicenter Retrospective Cohort Study.
To investigate whether the etiology of diminished ovarian reserve (DOR) independently influences outcomes of assisted reproductive technology (ART).
Published: July 31, 2026, midnight
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial - Yahoo Finance
Merck (MRK) Says KEYTRUDA Beat Chemotherapy In Phase 3 Endometrial Cancer Trial Yahoo Finance
Published: July 27, 2026, 10:08 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Sahm
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Sahm
Published: July 16, 2026, 10:27 a.m.
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk
Published: July 15, 2026, 11:49 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Benzinga
Published: July 15, 2026, 5:25 p.m.
Link copied to clipboard!